Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Profound Medical (PROF) Receivables (2018 - 2026)

Profound Medical has reported Receivables over the past 8 years, most recently at $7.7 million for Q4 2025.

  • For Q4 2025, Receivables rose 4.7% year-over-year to $7.7 million; the TTM value through Dec 2025 reached $7.7 million, up 4.7%, while the annual FY2025 figure was $7.7 million, 4.7% up from the prior year.
  • Receivables for Q4 2025 was $7.7 million at Profound Medical, down from $8.3 million in the prior quarter.
  • Over five years, Receivables peaked at $8.3 million in Q3 2025 and troughed at $4.3 million in Q2 2025.
  • A 5-year average of $6.3 million and a median of $6.4 million in 2022 define the central range for Receivables.
  • Biggest five-year swings in Receivables: rose 25.41% in 2022 and later tumbled 38.49% in 2025.
  • Year by year, Receivables stood at $5.1 million in 2021, then grew by 25.41% to $6.4 million in 2022, then rose by 16.53% to $7.4 million in 2023, then dropped by 0.72% to $7.4 million in 2024, then grew by 4.7% to $7.7 million in 2025.
  • Business Quant data shows Receivables for PROF at $7.7 million in Q4 2025, $8.3 million in Q3 2025, and $4.3 million in Q2 2025.